艾芦库单抗

艾芦库单抗（INN：Icrucumab；开发代号：IMC-18F1）是一种人单克隆抗体，设计用于治疗实体瘤。^[1][2]艾芦库单抗由ImClone Systems（英语：ImClone Systems）公司开发，正在进行I期试验。^[3]

艾芦库单抗

单克隆抗体
种类	完整抗体
目标	VEGFR（英语：VEGF receptor）-1
临床资料
其他名称	IMC-18F1
ATC码	未分配
识别信息
CAS号	1024603-92-6  N
ChemSpider	none
UNII	T7H0B1R64U
KEGG	D09926
化学信息
化学式	C6514H10024N1756O2032S42
摩尔质量	146,796.63 g·mol−1

参考资料

1. Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab (PDF). American Medical Association. [2024-01-21]. （原始内容存档 (PDF)于2012-09-28）.
2. LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. April 2014, 32 (2): 303–11. PMID 23903897. S2CID 34756277. doi:10.1007/s10637-013-9998-8.
3. Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov